Skip to main content
. 2011 Mar 3;13(5):509–516. doi: 10.1093/neuonc/nor017

Table 4.

Adverse events possibly, probably, or definitely related to romidepsin use, in the phase II component (n = 40)

Adverse event Grade 1 Grade 2 Grade 3 Grade 4
Hematologic
 Anemia 8 0 0 0
 Leucopenia 1 6 1 0
 Neutropenia 1 0 6 0
 Lymphopenia 1 4 4 0
 Thrombocytopenia 13 2 0 0
Nonhematologic
 Ventricular arrhythmia 1 0 0 0
 Cardiac general 0 0 1 0
 Hypotension 0 0 1 0
 PT prolongation 1 0 0 0
 Fatigue 7 6 3 1
 Fever without neutropenia 1 0 0 0
 Weight loss 1 0 0 0
 Alopecia 1 0 0 0
 Dry skin 1 0 0 0
 Injection site reaction 0 0 1 0
 Pruritis 0 1 0 0
 Skin rash 2 0 1 0
 Anorexia 4 0 0 0
 Constipation 6 0 1 0
 Diarrhea 3 1 0 0
 Dry mouth 1 0 0 0
 Flatulence 0 1 0 0
 Heartburn 1 1 0 0
 Mucositis 0 1 0 0
 Nausea 11 2 0 0
 Taste alteration 1 0 0 0
 Vomiting 1 1 1 0
 Petechiae 1 0 0 0
 Edema–limb 1 1 0 0
 ALT elevation 7 0 1 0
 AST elevation 0 1 0 0
 Alkaline phosphatase elevation 1 0 0 0
 Bilirubin elevation 0 1 0 0
 Cholesterol elevation 0 1 0 0
 Creatinine elevation 1 0 0 0
 Hyperglycemia 1 3 0 0
 Hypermagnesemia 1 0 0 0
 Hypoalbuminemia 1 0 0 0
 Hypocalcemia 2 0 0 0
 Hypokalemia 3 0 0 0
 Hypomagnesemia 1 0 0 0
 Hyponatremia 1 0 0 0
 Hypophosphatemia 2 2 1 0
 Muscle weakness (lower extremity) 0 2 0 0
 Muscle weakness (whole body) 0 1 0 0
 Extremity-upper (function) 0 1 0 0
 Joint–function 1 0 0 0
 Confusion 1 0 0 0
 Dizziness 1 2 0 0
 Blurred vision 1 0 0 0
 Abdominal pain 3 0 0 0
 Chest/thorax pain 1 0 0 0
 Limb pain 1 0 0 0
 Headache 0 1 0 0
 Joint pain 2 1 0 0
 Thrombosis or embolism of vascular access 0 0 0 1

ALT, alanine aminotransferse; AST, aspartate aminotransferase; and PT, prothrombin time.